<DOC>
	<DOC>NCT01109524</DOC>
	<brief_summary>The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.</brief_summary>
	<brief_title>Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>NonSmall Cell Lung Cancer (NSCLC), Stage IV (per the American Joint Committee on Cancer (AJCC) Staging Manual, Seventh Edition) or recurrent disease following surgery and/or radiation therapy Evaluable or measurable disease Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 Uncontrolled Central Nervous System (CNS) metastasis. Previous exposure to monoclonal antibodies, signal transduction inhibitors or Epidermal growth factor receptor (EGFR) targeting therapy Concurrent malignancy Prior chemotherapy for NSCLC Preexisting ascites grade ≥ 2 or pericardial effusion grade ≥ 2 Superior vena cava syndrome contraindicating hydration White Blood Cells (WBC) &lt; 3,000/mm³ Absolute neutrophile count (ANC) &lt; 1,500/mm³ Platelet &lt; 100,000/mm³ Hemoglobin (Hgb) &lt; 9.0 g/dL Total bilirubin &gt; 1.5 x Upper limit of normal (ULN). Aspartate aminotransferase (AST) or Alanineaminotransferase (ALT) &gt; 5.0 x ULN. Serum creatinine &gt;1.25 x ULN and calculated creatinine clearance &lt;60mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>